Edition:
United States

Peregrine Pharmaceuticals Inc (PPHM.OQ)

PPHM.OQ on NASDAQ Stock Exchange Capital Market

0.73USD
27 Mar 2017
Change (% chg)

-- (--)
Prev Close
$0.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
525,178
52-wk High
$0.77
52-wk Low
$0.28

Latest Key Developments (Source: Significant Developments)

Peregrine Pharmaceuticals Q3 loss per share $0.04
Monday, 13 Mar 2017 04:37pm EDT 

Peregrine Pharmaceuticals Inc : Sees FY 2017 revenue from avid bioservices business of $60 million-$65 million . Increasing FY Avid Bioservices business manufacturing revenue outlook to $60 - $65 million from $50 - $55 million . Peregrine pharmaceuticals reports financial results for the third quarter of fiscal year 2017 and recent developments .Q3 loss per share $0.04.  Full Article

Peregrine Pharmaceuticals Q4 loss per share $0.05
Thursday, 14 Jul 2016 04:05pm EDT 

Peregrine Pharmaceuticals Inc : Peregrine pharmaceuticals reports financial results for quarter and fiscal year ended april 30, 2016 and recent developments . Q4 loss per share $0.05 . Q4 revenue $18.78 million versus i/b/e/s view $15.8 million . Q4 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S . Peregrine pharmaceuticals inc says analysis of data from sunrise phase iii trial ongoing with new clinical trials expected to commence late 2016 to early 2017 .Says Growing Biomanufacturing Demand Prompts Plans For Third Manufacturing Facility Expected To Be Commissioned By Mid 2017.  Full Article

Peregrine Pharmaceuticals declares quarterly dividend
Monday, 7 Dec 2015 04:00pm EST 

Peregrine Pharmaceuticals:Declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock.The quarterly dividend on the Series E Preferred Stock is payable on January 4, 2016 to holders of record at the close of business on December 18, 2015.The quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share.  Full Article

Peregrine Pharmaceuticals Inc declares quarterly dividend on its Series E Convertible preferred stock
Tuesday, 8 Sep 2015 04:05pm EDT 

Peregrine Pharmaceuticals Inc:Declares quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock.Payable on Oct. 1 to holders of record at the close of business on Sept. 18.Quarterly dividend payment on the Series E Preferred Stock will be $0.65625 per share.  Full Article

Peregrine Pharmaceuticals Inc data presented at AACR demonstrate synergistic anti-tumor effects of peregrine pharmaceuticals' phosphatidylserine (PS)
Tuesday, 21 Apr 2015 08:00am EDT 

Peregrine Pharmaceuticals Inc:Says presentation of data from preclinical studies demonstrating combination of phosphatidylserine (PS) blockade with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors promoted strong, localized and enhanced efficacy in models of melanoma and breast cancer.Says these data were presented at 106th Annual Meeting of the American Association for Cancer Research (AACR) being held in Philadelphia, Pennsylvania from April 18-22, 2015.Says Peregrine's lead PS-blocking antibody, bavituximab, is currently being evaluated in second-line non-small cell lung cancer (NSCLC) in Phase III clinical trial named Sunrise.  Full Article

More From Around the Web

BRIEF-Peregrine Pharmaceuticals Q3 loss per share $0.04

* Sees FY 2017 revenue from avid bioservices business of $60 million-$65 million